title: Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers.
abstract: Promising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines madeRAS(KRASandNRAS) status a prerequisite for the use of anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new data emerge on the theranostic and prognostic role of molecular biomarkers, which is a strong incentive for a validated, sensitive and broadly available molecular screening test in order to implement and improve multi-modal therapy strategy and clinical trials. Next generation sequencing (NGS) has begun to supplant other technologies for genomic profiling. Targeted NGS is a method that allows parallel sequencing of thousands of short DNA sequences in a single test offering a cost-effective approach for detecting multiple genetic alterations with a minimum amount of DNA. In the present review, we collected data concerning the clinical application of NGS technology in the setting of colorectal cancer.
authors.affiliation: Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium. quitterie.fontanges@erasme.ulb.ac.be.
authors.forename: Quitterie
authors.initials: Q
authors.lastname: Fontanges
authors.affiliation: Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium. ricardo.de.mendonca@erasme.ulb.ac.be.
authors.forename: Ricardo
authors.initials: R
authors.lastname: De Mendonca
authors.affiliation: Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium. isabelle.salmon@erasme.ulb.ac.be.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Salmon
authors.affiliation: Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium. marie.le.mercier@erasme.ulb.ac.be.
authors.forename: Marie
authors.initials: M
authors.lastname: Le Mercier
authors.affiliation: Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium. nicky.d.haene@erasme.ulb.ac.be.
authors.forename: Nicky
authors.initials: N
authors.lastname: D'Haene
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000235:genetics; D000068818:Cetuximab / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D020558:GTP Phosphohydrolases / Q000235:genetics*; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics*; D000077544:Panitumumab; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D017422:Sequence Analysis, DNA
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C117307:KRAS protein, human; D008565:Membrane Proteins; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020558:GTP Phosphohydrolases; C579846:NRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras); D000068818:Cetuximab
keywords: clinical application; colorectal cancer; targeted next generation sequencing